| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e9e0b17a7397b2f1b810b713a0e7651 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-42 |
| filingDate |
2005-03-28^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-02-22^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_214a3d26d43915885148e56e41adae51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac2769cf6e46d5ff6299e581fcc74a6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_936c39f29fe18045ece73234329ceabf |
| publicationDate |
2011-02-22^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7893261-B2 |
| titleOfInvention |
Serotonin reuptake inhibitors |
| abstract |
A serotonin reuptake inhibitor which can be used in the treatment of depression and which has a decreased occurrence of unwanted side effects. The serotonin reuptake inhibitors are bi-functional organic molecules which combine serotonin transporter reuptake inhibition with serotonin (5-HT, such as 5-HT2A) receptor antagonism in one molecular entity. The serotonin-selective reuptake inhibitor (SSRI) homologue portion of the molecule shows an affinity to the serotonin reuptake transporter (SERT) and has antidepressant properties. The piperazine or piperidine portion of the molecule demonstrates an affinity to 5-HT receptors and restores the undesired side effects of SSRIs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013074676-A2 |
| priorityDate |
2004-03-26^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |